Alacra Pulse Banner
 

CVS Caremark Corp (CVS)

Search Street Pulse:
 
 
Follow Alacra Pulse on Twitter
Latest Analyst Comments on CVS Caremark Corp (CVS)
 

Citigroup Reiterates CVS Caremark Buy Rating Following Q4 Results (CVS) (Comtex Smartrend) - 08:33 ET Feb 09, 2010

Citigroup analyst Deborah L Weinswig said that the company's earnings were inline with consensus estimate as well as their estimates and that CVS reiterated its 2010 EBIT guidance for PBM and retail segments Furthermore, the company provided 2010 guidance that was inline with consensus estimates However, Citigroup sees its guidance on the conservative end Weinswig said, "Management noted that LDG has already exceeded profitability targets driven by strong margin performance and solid expense management 
Deborah Weinswig
Deborah Weinswig
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  Citigroup analyst Deborah L Weinswig said that the company's earnings were inline with consensus estimate as well as their estimates and that <span class="company">CVS</span> reiterated its 2010 EBIT guidance for PBM and retail segments Tweet this 

CVS reports profits up 11% in 4th quarter (Honolulu Advertiser - Business) - 02:41 ET Feb 09, 2010

In a note to clients, Deutsche Bank analyst Bill Dreher said CVS is gaining market share, and sales at stores open at least a year are still better than at rivals like Walgreen and Rite Aid He said clients do like CVS' Maintenance Choice program, which allows plan members to pick up 90 day prescriptions at CVS stores rather than get them by mail During the fourth quarter, the company opened 23 retail pharmacies, relocated eight and closed six It also closed two specialty pharmacies, leaving it with 49 
Bill Dreher
Bill Dreher
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  In a note to clients, Deutsche Bank analyst <span class="analyst">Bill Dreher</span> said <span class="company">CVS</span> is gaining market share, and sales at stores open at least a year are still better than at rivals like Walgreen and Rite Aid Tweet this 

CVS Caremark PBM Turning a Corner? (Morningstar Stock Analyst Notes) - 18:41 ET Feb 08, 2010

CVS Caremark PBM Turning a Corner? Print Note Reprints Comment Recommend ( ) by Matthew Coffina | 02 08 10 | 5:33PM | E mail Note 
 
Share:  <span class="company">CVS Caremark</span> PBM Turning a Corner? Print Note Reprints Comment Recommend ( ) by Matthew Coffina | 02 08 10 | 5:33PM | E mail Note Tweet this 

CVS Caremark profit tops view; shares jump (International Business Times) - 13:40 ET Feb 08, 2010

CVS also said 2010 earnings could top analysts' expectations. Just three months ago, CVS shocked investors when it said the pharmacy benefits business, which administers prescription drug benefits for employers and health plans and operates a large mail order pharmacy, lost out on about $48 billion of business heading into 2010, leading to the departure of the unit's president During Monday's quarterly call the new PBM president explained that problems were isolated and have since been fixed Per Lofberg said he has not seen any problems with client satisfaction during his first month on the job "The PBM seems to have stabilized a little bit already," said Jefferies & Co analyst Scott Mushkin 
Scott Mushkin
Scott Mushkin
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  Per Lofberg said he has not seen any problems with client satisfaction during his first month on the job "The PBM seems to have stabilized a little bit already," said Jefferies & Co analyst <span class="analyst">Scott Mushkin</span> Tweet this 

CVS Caremark Corporation at JPMorgan Healthcare Conference (Thomson Street Events) - Jan 13, 2010

Lisa Gill - JPMorgan - Analyst Good morning. My name is Lisa Gill, and I am the healthcare, technology and distribution analyst with JPMorgan. With us this morning we have CVS Caremark. Nearly three years ago, there was a transformational deal that was done between Caremark and CVS to create this healthcare services company. To talk in more detail this morning, I have with me Tom Ryan. But also, we have with us this morning their new CFO, David Denton, will be with us in the breakout session, as well as Per Lofberg, who was recently named the President of the PBM. So with that, I'm going to turn it over to Tom, and ask that you hold your questions until we're in the breakout room across the hall in the Borsia. With that, Tom? Tom Ryan - CVS Caremark Corporation - Chairman, President, CEO Okay, thanks, Lisa. Good morning, everybody. Today, this morning, what I'd like to do is give you a brief overview of the Company and a little bit of where we are positioned for future growth; talk about 
 
Share:  ...Lisa Gill - JPMorgan - Analyst Good morning. My name is Lisa Gill, and I am the healthcare, technology and distribution analyst with JPMorgan. With us this morning we have CVS Caremark. Nearly three years ago, there was a transformational deal that was done between Caremark and CVS to create this healthcare services company. To talk in more detail this morning, I have with me Tom Ryan. But also, we have with us this morning their new CFO, David Denton, will be with us in the breakout session, as well as Per Lofberg, who was recently named the President of the PBM. So with that, I'm going to turn it over to Tom, and ask that you hold your questions until we're in the breakout room across the hall in the Borsia. With that, Tom? Tom Ryan - CVS Caremark Corporation - Chairman, President, CEO Okay, thanks, Lisa. Good morning, everybody. Today, this morning, what I'd like to do is give you a brief overview of the Company and a little bit of where we are positioned for future growth; talk about... Tweet this 

Drugstore Strength Could Mean Upside for Consumer ETF (The Street: Banks) - 13:03 ET Feb 08, 2010

This instrument's exposure to pharmacy giants CVS Caremark ( CVX , commentary , Trade Now ) and Walgreen ( WAG , commentary , Trade Now ) is the strongest in the ETF universe Together, these two firms account for 8% of the fund's portfolio Although CVS reported fourth quarter revenue that slightly missed the target set by analysts, the company reported an 11% increase in profit during the three month period 
 
Share:  This instrument's exposure to pharmacy giants <span class="company">CVS Caremark</span> ( CVX , commentary , Trade Now ) and Walgreen ( WAG , commentary , Trade Now ) is the strongest in the ETF universe Tweet this 

CVS profit grows on pharmacy business (Contra Costa Times - Business) - 13:00 ET Feb 08, 2010

In a note to clients, Deutsche Bank analyst Bill Dreher said CVS is gaining market share, and sales at stores open at least a year are still better than rivals like Walgreen and Rite Aid He said clients like CVS's Maintenance Choice program, which allows plan members to pick up 90 day prescriptions at CVS stores rather than getting them by mail During the fourth quarter, the company opened 23 retail pharmacies, relocated eight, and closed six It also closed two specialty pharmacies, leaving it with 49 
Bill Dreher
Bill Dreher
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  In a note to clients, Deutsche Bank analyst <span class="analyst">Bill Dreher</span> said <span class="company">CVS</span> is gaining market share, and sales at stores open at least a year are still better than rivals like Walgreen and Rite Aid Tweet this 

CVS sales outpacing Walgreen, Rite Aid (Providence Business News) - 11:04 ET Feb 08, 2010

Same store retail pharmacy sales rose 73 percent from a year earlier in a sign the company is taking share from competitors, Jefferies & Co analyst Scott Mushkin told Dow Jones CVS rivals Walgreen Co and Rite Aid Corp both said their same store pharmacy sales fell in January For the full year, CVS posted a profit of $37 billion, or $258 a share, up from a profit of $321 billion, or $223 a share, a year earlier Revenue rose 13 percent to $9873 billion Additional information is available at cvscaremarkcom 
Scott Mushkin
Scott Mushkin
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  Same store retail pharmacy sales rose 73 percent from a year earlier in a sign the company is taking share from competitors, Jefferies & Co analyst <span class="analyst">Scott Mushkin</span> told Dow Jones Tweet this 

Investors cheered the results In early trading on the New York Stock Exchange, CVS shares rose 55 percent to $3279 at 10:23 am Matt Perry, an analyst at Wachovia, told Reuters the earnings report was "decent, especially in the face of a tough economy" CVS Caremark's pharmacy benefit management (PBM) division, which is being overhauled after losing $48 billion in contracts for this year, posted a 15 percent jump in revenue even as total claims processed decreased 56 percent CVS Chairman, President and Chief Executive Officer Thomas M Ryan expressed optimism that the company would see a turnaround in the PBM unit next year 
Matthew Perry
Matthew Perry
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  <span class="analyst">Matt Perry</span>, an analyst at Wachovia, told Reuters the earnings report was "decent, especially in the face of a tough economy" Tweet this 

UPDATE: CVS Caremark 4Q Profit Rises 10% Amid Revenue Strength (Fox Business) - Feb 08, 2010

At its pharmacy benefits business, revenue rose 15% despite a 56% drop in claims processed, mostly owing to the termination of two big health plan clients at the start of 2009 and three fewer reporting days in the period That segment has been under scrutiny since late last year, when CVS said the Caremark business lost a net $48 billion in 2010 contracts At that time, CVS also said Caremark's operating profit could decline by 10% to 12% this year It rose just 3% in the fourth quarter on falling margins CVS/Caremark's same store pharmacy sales, which grew 73% in the fourth quarter, indicate the company is taking share from some competitors, said Scott Mushkin, analyst at Jefferies & Co 
Scott Mushkin
Scott Mushkin
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  <span class="company">CVS</span>/Caremark's same store pharmacy sales, which grew 73% in the fourth quarter, indicate the company is taking share from some competitors, said <span class="analyst">Scott Mushkin</span>, analyst at Jefferies & Co Tweet this 

Morning Watch, Feb. 8 (Optionetics) - Feb 08, 2010

Earnings this morning will be highlighted by CVS Caremark ( CVS ), Electronic Arts ( ERTS ) and Hasbro ( HAS ) Earnings have been mostly better than expected, but this has not necessarily led to gains for these stocks In fact, reaction to earnings has been unpredictable, showing that traders aren't sure what to make of the future 
Jody Osborne
Jody Osborne
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  Earnings this morning will be highlighted by <span class="company">CVS</span> Caremark ( <span class="company">CVS</span> ), Electronic Arts ( ERTS ) and Hasbro ( HAS ) Earnings have been mostly better than expected, but this has not necessarily led to gains for these stocks Tweet this 

CVS Caremark Beats by a Penny (Zacks - Analyst Blog) - Feb 08, 2010

CVS Caremark's ( ) fourth quarter earnings came in at 79 cents per share, a cent above the Zacks Consensus Estimate of 78 cents and higher than 70 cents reported in the year ago period. Revenues increased 7% year over year to $258 billion primarily due to robust growth of both segments , Pharmacy Services and Retail Pharmacy For the full year 2009, CVS reported earnings per share of $274 compared to $244 in 2008 
 
Share:  <span class="company">CVS Caremark</span>'s ( ) fourth quarter earnings came in at 79 cents per share, a cent above the Zacks Consensus Estimate of 78 cents and higher than 70 cents reported in the year ago period. Tweet this 

Karen Finerman Building A Position In CVS Caremark (CVS) (Benzinga) - Feb 05, 2010

She highlighted this pick earlier in the week at the Harbor Investment Conference Finerman said that at the current stock price, you are buying CVS Caremark's Pharmacy Benefit Management division at 7 times earnings She said that she has a great deal of conviction in this stock Furthermore, Jim Cramer just called CVS very cheap on Mad Money, and said that depending on the earnings numbers which will be released on Monday morning, he may be recommending the stock at the beginning of next week Wall Street analysts are expecting EPS of $078 versus $070 in the year ago period 
Jim Cramer
Jim Cramer
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  Furthermore, <span class="analyst">Jim Cramer</span> just called CVS very cheap on Mad Money, and said that depending on the earnings numbers which will be released on Monday morning, he may be recommending the stock at the beginning of next week Tweet this 

Bloomberg: Profit Windfall Ahead for Drug Store Chains (The Razor''s Edge) - Feb 05, 2010

Bloomberg.com is running a story about an underreported potential windfall for the nation's largest drug store chains Walgreen ( WAG ) and CVS Caremark ( CVS ). The reason for the optimism is the end of patent protection for the world's two best selling drugs Lipitor and Plavix Soon after blockbuster drugs lose patent protection is a very profitable time for drug stores as they have more control over pricing, and even though generic drugs are cheaper than branded drugs, they generally provide better profit margins for the pharmacies 
 
Share:  Bloomberg.com is running a story about an underreported potential windfall for the nation's largest drug store chains Walgreen ( WAG ) and <span class="company">CVS</span> Caremark ( <span class="company">CVS</span> ). Tweet this 

Goldman Sachs takes CVS off recommended buy list (Forbes) - Feb 03, 2010

A Goldman Sachs analyst took CVS Caremark Corp shares off a list of recommended stocks Wednesday following a recovery in the drugstore chain's stock price John Heinbockel took the stock off Goldman's Americas Conviction Buy List, which contains stocks with the strongest "Buy" rating He still has a "Buy" rating on shares of the Woonsocket, RI, company CVS Caremark shares dropped 20 percent on Nov 5 after the company reported billions of dollars in contract losses for its Caremark pharmacy benefits management unit 
John Heinbockel
John Heinbockel
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  <span class="analyst">John Heinbockel</span> took the stock off Goldman's Americas Conviction Buy List, which contains stocks with the strongest "Buy" rating Tweet this 

Goldman Sachs Removed CVS Caremark (CVS) from Conviction Buy List (StreetInsider - Conviction Buy List) - Feb 03, 2010

Goldman Sachs removed CVS Caremark Corp (NYSE: CVS ) from their Conviction Buy List, but maintains a Buy rating on the shares 
 
Share:  <span class="analyst">Goldman Sachs</span> removed <span class="company">CVS</span> Caremark Corp (NYSE: <span class="company">CVS</span> ) from their Conviction Buy List, but maintains a Buy rating on the shares Tweet this 

Acquisition Means More Business For Pharmacy Benefits Manager (Investor''s Business Daily - Business) - Jan 29, 2010

In 2006, it attempted a $26 billion hostile takeover of Caremark Rx, losing to CVS Integration of an acquisition always has risks, says George Hill, an analyst with Leerink Swann 
George Hill
George Hill
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  In 2006, it attempted a $26 billion hostile takeover of Caremark Rx, losing to <span class="company">CVS</span> Integration of an acquisition always has risks, says <span class="analyst">George Hill</span>, an analyst with Leerink Swann Tweet this 

Caremark wins pharmacy contract for Tennessee employees (tennessean.com - Business) - Jan 27, 2010

Winning the award has implications beyond dollars and cents as the nation's largest purchaser of drugs attempts to rebound from recent contract losses in other states and with other customers here "It's just good to see them getting back on the track of winning contracts," said Jeff Jonas, an analyst at Gabelli & Co in Rye, NY, which owns shares in CVS Caremark on behalf of clients "They're certainly going to be competitive on the price, given their size and the purchasing contracts they get from drug companies I think it's just a matter of marketing and presenting it correctly to the client" Including discounts that Caremark would pass along, and the company's administrative fees, the state expects to spend $138 billion on prescription drugs over the next five years 
Jeffrey Jonas
Jeffrey Jonas
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  "It's just good to see them getting back on the track of winning contracts," said <span class="analyst">Jeff Jonas</span>, an analyst at Gabelli & Co in Rye, NY, which owns shares in <span class="company">CVS Caremark</span> on behalf of clients Tweet this 

Raymond James' Top Analyst Picks for 2010 (Seeking Alpha (blog)) - Jan 05, 2010

Raymond James analysts argue that CVS now has compelling relative valuation and that you could potentially be getting its PBM essentially for free 
 
Share:  <span class="analyst">Raymond James</span> analysts argue that <span class="company">CVS</span> now has compelling relative valuation and that you could potentially be getting its PBM essentially for free Tweet this 

Analysts' Best Stock Picks For 2010 (market folly) - Jan 04, 2010

Raymond James analysts argue that CVS now has compelling relative valuation and that you could potentially be getting their PBM essentially for free 
 
Share:  <span class="analyst">Raymond James</span> analysts argue that <span class="company">CVS</span> now has compelling relative valuation and that you could potentially be getting their PBM essentially for free Tweet this 

Potential Drug-Benefit Company Tax Hard To Gauge Now (NASDAQ) - Dec 17, 2009

By Dinah Wisenberg Brin, Of DOW JONES NEWSWIRES Pharmacy benefit managers face some uncertainty over prospects for a new tax to help pay for a national health care overhaul, although analysts at this point can only speculate on the potential effects if lawmakers impose such a levy Stocks of the major managed care companies Medco Health Solutions Inc (MHS), Express Scripts Inc (ESRX) and CVS Caremark Corp (CVS) traded roughly flat Thursday after slipping the previous day amid speculation that senators might include an industry tax in their health overhaul bill The effect of such a tax on PBMs, should it be approved, "is simply unknowable at this point," Lazard Capital Markets analyst Tom Gallucci said, noting that details are "nonexistent" and that the House health care bill doesn't call for a PBM tax Senators apparently were considering a PBM tax as a way to pay for the Medicare prescription drug benefit doughnut hole the part of the program for which seniors must pay out of pocket for their medicines The industry trade group, the Pharmaceutical Care Management Association, said the tax would increase premiums and out of pocket costs for consumers and the unions and employers who provide their prescription drug benefits 
Thomas Gallucci
Thomas Gallucci
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.  
Share:  The effect of such a tax on PBMs, should it be approved, "is simply unknowable at this point," Lazard Capital Markets analyst <span class="analyst">Tom Gallucci</span> said, noting that details are "nonexistent" and that the House health care bill doesn't call for a PBM tax Tweet this 

Analyst Comment Ticker
 
Key:
  • Sell-side Sell-side
  • Blog Blog
  • Credit Analyst Credit
  • Industry Analyst Industry

Copyright © 2010 Alacra, Inc., 100 Broadway, Suite 1100, New York, NY 10005. All rights reserved.

Reproduction in whole or in part in any form or medium without express written permission is prohibited.